Troriluzole Shows Potential to Treat Moderate Alzheimer’s in Phase 2/3 Trial, Monitoring Board Rules

Troriluzole Shows Potential to Treat Moderate Alzheimer’s in Phase 2/3 Trial, Monitoring Board Rules
Troriluzole, an investigational oral therapy by Biohaven, shows a potential to improve cognition and lessen brain volume loss, a sign of Alzheimer's disease progression, a board reviewing the ongoing Phase 2/3 trial decided. The trial successfully completed its interim futility analysis — meaning it can efficiently reach preset goals measuring benefit — and can continue treating patients toward that end, its independent Data Safety Monitoring Board found. "We believe that troriluzole is a promising potential therapy for people suffering from the devastating impact of Alzheimer's disease," Irfan Qureshi, vice president of neurology at Biohaven, said in a press release. "We are very excited that the T2 Protect AD Study, which recently completed enrollment, has now passed the interim futility analysis." Trigriluzole (BHV-4157) is a new compound precursor of riluzole — an approved amyotrophic lateral sclerosis (ALS) treatment — designed to regulate glutamate activity, one of the most abundant and important signaling molecules in the brain. Unusual sensitivity to glutamate — or excessively high levels of this molecule — can damage and kill nerve cells. Troriluzole acts by increasing the expression and function of EAAT2, a transporter that is used by bra
Subscribe or to access all post and page content.